How Peptide Doping Is Detected in 2026
Peptides and Sports Doping
46 peptides detectable
A single dried blood spot can now be screened for 46 prohibited peptide and non-peptide doping agents using automated sample preparation and high-resolution mass spectrometry, with detection limits as low as 0.5 ng/mL.
Lange et al., Anal Bioanal Chem, 2020
Lange et al., Anal Bioanal Chem, 2020
View as imageIn 2024, a 19-year-old American speed skater received a one-year ban after testing positive for BPC-157. The same year, a Canadian volleyball player received a four-year ban for BPC-157 and TB-500. These cases illustrate a shift in anti-doping enforcement: peptide hormones that were once considered undetectable are now routinely identified in athlete biological samples using liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS).
The 2026 WADA Prohibited List bans peptide hormones, growth factors, and related substances under category S2, explicitly naming growth hormone releasing peptides (GHRP-1 through GHRP-6), growth hormone releasing hormone analogues (CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (ibutamoren/MK-677), thymosin beta-4 derivatives (TB-500), and erythropoietin-based agents. BPC-157 falls under the S0 "non-approved substances" category, prohibited at all times with no therapeutic use exemption available.
This article maps the technology behind peptide doping detection: how samples are collected and prepared, what instruments identify banned peptides, how metabolites extend detection windows, and where the gaps remain. Each major section connects to a dedicated cluster article exploring specific substance classes.
Key Takeaways
- LC-HRMS (liquid chromatography-high resolution mass spectrometry) is the primary technology for detecting banned peptides, capable of screening 41-54 substances in a single analytical run with detection limits of 0.20-0.92 ng/mL in urine (Chang et al., 2021)
- Dried blood spots can be screened for 46 peptide doping agents using fully automated sample preparation, with confirmed detection of GHRP-2 and GHRP-6 in real doping control samples (Lange et al., 2020)
- BPC-157 metabolites have been mapped using stable isotope labeling, identifying 9 metabolites including one from a novel pathway, with urine detection limits of 0.01-0.11 ng/mL (Tian et al., 2023)
- TB-500 doping can be detected through non-natural synthesis impurities that distinguish synthetic peptide from endogenous thymosin beta-4 (Delcourt et al., 2025)
- Ghrelin, despite being WADA-banned, may not be detectable in urine by mass spectrometry, suggesting blood-based testing is required for this peptide (Thomas et al., 2021)
- Growth hormone releasing peptides are detected primarily through their metabolites, with the GHRP-2 metabolite detectable for 20 hours after a single oral dose (Thomas et al., 2011)
The Core Technology: LC-HRMS
The analytical backbone of modern peptide doping detection is liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). This technology separates peptides by their chemical properties (chromatography), then identifies them by their exact molecular mass and fragmentation patterns (mass spectrometry).
Judak et al. (2021) reviewed a decade of progress in this field, noting that high-resolution mass spectrometers have become the preferred detection instrument in WADA-accredited laboratories.[1] The resolution exceeds 100,000 full width at half maximum, meaning the instrument can distinguish between molecules that differ by less than 0.001 atomic mass units. This precision is critical because biological samples contain thousands of endogenous peptides, proteins, and metabolites that could interfere with detection of banned substances.
Chang et al. (2021) developed a method that screens 41 prohibited small peptides and 3 non-peptide growth hormone secretagogues in a single analytical run of 14 minutes per sample. Using parallel reaction monitoring (PRM) mode, they achieved detection limits of 0.20-0.92 ng/mL in urine, meeting WADA's Minimum Required Performance Levels. The method was validated across more than 5,000 samples with no false positives or false negatives.[2]
Thomas et al. (2022) extended testing to blood samples, demonstrating that a generic mixed-mode solid-phase extraction could co-extract and detect multiple classes of peptidic drugs (2-10 kDa) including insulins, growth hormone releasing hormones (sermorelin, CJC-1295, tesamorelin), insulin-like growth factors, and mechano growth factors, all within WADA performance requirements.[3] Blood-based analysis detects intact peptides at higher concentrations than urine, where peptides are often degraded. For a deeper look at which specific peptides are on the banned list, see our article on WADA's prohibited peptide list.
Sample Collection: From Venipuncture to Dried Blood Spots
Traditional doping control requires venipuncture blood draws and supervised urine collection, but the field is moving toward less invasive approaches. Lange et al. (2020) demonstrated that dried blood spots (DBS), requiring only a finger prick, can be screened for 46 lower molecular mass peptide and non-peptide doping agents using fully automated sample preparation.[4]
Their method combined robotic near-infrared spectroscopy for hematocrit measurement (correcting for blood thickness variation), automated strong cation exchange solid-phase extraction, and LC-HRMS detection. Target analytes included agonists of the GnRH receptor, ghrelin receptor, growth hormone receptor, and antidiuretic hormone receptor. Detection limits ranged from 0.5 to 20 ng/mL. As proof of concept, the method confirmed GHRP-2 and GHRP-6 in authentic post-administration doping control samples.
The DBS approach also incorporated several glycine derivatives of growth hormone releasing peptides that were arguably designed specifically to evade current testing methods, demonstrating that anti-doping science is tracking designer peptide analogues in parallel with established substances. Blood can also be collected using microneedle devices from the upper arm, offering a nearly painless alternative to traditional draws while maintaining analytical validity.
The shift toward DBS is significant for out-of-competition testing, which is where most peptide doping is likely to occur. Athletes typically use recovery-enhancing peptides between training sessions and competitions, not on competition day. Out-of-competition blood draws require trained phlebotomists and cold chain logistics; DBS cards can be collected by any trained doping control officer, stored at room temperature, and mailed to the laboratory. This dramatically expands the practical reach of blood-based peptide testing into situations where venipuncture would be impractical.
Detecting Specific Banned Peptides
BPC-157
BPC-157 presents a detection challenge because it is a 15-amino-acid peptide fragment (a partial sequence of a protein found in gastric juice) with no approved medical use and therefore no established pharmacokinetic data in humans. Tian et al. (2023) addressed this by using stable isotope labeling with 13C/15N-labeled BPC-157 combined with UHPLC-HRMS to map the peptide's metabolic profile.[5] They identified 9 metabolites: 8 produced by conventional amide-bond cleavage (the peptide breaking into smaller fragments) and 1 from a previously unknown metabolic pathway. A validated urine detection method achieved limits of 0.01-0.11 ng/mL with recovery rates above 90%.
Earlier work demonstrated BPC-157 detectability in urine for at least 72 hours using weak cation exchange solid-phase extraction protocols. The expanded metabolite panel from the 2023 study extends the detection window because metabolites persist longer than the parent peptide. The eight metabolites produced by amide-bond cleavage represent the peptide being cut at different positions along its 15-amino-acid chain, producing fragments of varying sizes. Each fragment has a distinct mass and retention time in the chromatographic system, providing multiple independent confirmation signals for BPC-157 exposure. The ninth metabolite, produced by a previously uncharacterized pathway, offers an additional detection target that would be missed by methods designed around predicted cleavage products only. For a complete overview of BPC-157's regulatory status, see our article on BPC-157 and TB-500 in sports. For BPC-157's FDA classification, see our article on BPC-157 and the FDA.
TB-500 and Thymosin Beta-4
TB-500 is a synthetic acetylated fragment of thymosin beta-4 (TB4), a protein found in virtually all mammalian cells. The detection challenge is distinguishing exogenous synthetic TB-500 from endogenous TB4. Ho et al. (2012) developed the first confirmed detection method for N-acetylated LKKTETQ (TB-500's active sequence) and its metabolites in equine urine and plasma, achieving detection at 0.01-0.02 ng/mL.[6]
Delcourt et al. (2025) advanced the approach by establishing the first population reference range for endogenous TB4 in racehorse blood and demonstrating that synthetic TB4 products contain detectable non-natural synthesis impurities.[7] Their study found that TB4 concentrations are not affected by gender, age, or breed, but warned that delayed plasma separation causes rapid TB4 elevation due to cell lysis, a critical pre-analytical variable. The detection of manufacturing impurities from a single dose administration provides a definitive marker distinguishing synthetic from endogenous peptide.
Growth Hormone Releasing Peptides
GHRPs (GHRP-1 through GHRP-6, ipamorelin, hexarelin, alexamorelin) stimulate endogenous growth hormone secretion. Thomas et al. (2011) established detection methods for GHRPs and their metabolites in human urine, demonstrating that the GHRP-2 metabolite (D-Ala-D-2-naphthylAla-L-Ala) was detectable for 20 hours after a single 10 mg oral dose, while the intact peptide was not observed.[8] This finding is critical: testing for intact GHRPs in urine would miss most cases of misuse, because the parent peptides are rapidly metabolized. Detection strategies must target metabolites.
Philip et al. (2022) characterized 22 metabolites of ibutamoren (MK-0677), a non-peptide growth hormone secretagogue, in thoroughbred horses. Major metabolites were detectable up to 96 hours post-dose, while the parent compound persisted for 72 hours.[9] Ibutamoren is orally active and leaves a longer detection footprint than injectable peptide GHRPs, making it paradoxically easier to catch despite its classification as a "designer" secretagogue. For a dedicated exploration of why GH secretagogues are banned, see our article on growth hormone secretagogues and anti-doping.
Ghrelin
Ghrelin, the 28-amino-acid hunger hormone, is banned by WADA due to its growth hormone releasing properties. Thomas et al. (2021) developed LC-MS/MS methods for ghrelin and desacyl ghrelin in both plasma and urine, achieving detection limits of 30-50 pg/mL.[10] Plasma levels in healthy volunteers ranged from 30-100 pg/mL for ghrelin and 100-1,200 pg/mL for desacyl ghrelin.
The study produced a surprising and consequential finding: no endogenous ghrelin was detected in urine by mass spectrometry, despite adequate sensitivity. Earlier studies that reported urinary ghrelin used immunoassay-based methods, which are less specific and may have detected cross-reacting peptides rather than ghrelin itself. This means urine-based testing for ghrelin misuse may be fundamentally unreliable, and blood-based testing may be required.
For athletes, this has practical implications: ghrelin doping is more likely to be detected through the Athlete Biological Passport blood module than through standard urine screens. The distinction between acyl ghrelin (the biologically active form) and desacyl ghrelin (the inactive form, present at 10-12 times higher concentrations) adds analytical complexity. Both forms must be measured and their ratio interpreted in context, as exogenous ghrelin administration would be expected to alter the ratio differently than endogenous fluctuations from fasting or feeding. For more on GLP-1 agonists and WADA rules, see our article on GLP-1 agonists and WADA.
EPO, Insulin, and Larger Peptide Hormones
While this article focuses primarily on small peptides (<10 kDa), the detection landscape for larger peptide hormones has its own history and challenges. For a full exploration of EPO's role in endurance doping, see our article on EPO: the peptide that defined endurance doping.
Erythropoietin (EPO). Recombinant EPO detection relies on isoelectric focusing (IEF) to distinguish endogenous EPO from synthetic variants based on differences in glycosylation patterns. Newer EPO-mimetic agents like peginesatide and the recently listed pegmolesatide require separate mass spectrometry-based methods. The WADA Athlete Biological Passport hematological module tracks hemoglobin concentration and reticulocyte percentage over time, flagging abnormal patterns consistent with EPO use even when the drug itself is no longer detectable.
Insulin. Thomas et al. (2022) demonstrated that blood-based LC-HRMS methods can simultaneously detect human insulin and all major synthetic insulin analogues (lispro, aspart, glulisine, tresiba, detemir, glargine) as well as bovine and porcine insulin in a single analytical run.[3] Insulin abuse is primarily a concern in strength sports where athletes combine insulin with growth hormone to drive nutrient partitioning. Detection requires blood testing because insulin is metabolized before reaching urine in measurable quantities.
Growth hormone. Detecting exogenous growth hormone (rhGH) uses two complementary approaches: the isoform test, which measures the ratio of 22 kDa to 20 kDa GH isoforms (exogenous GH is pure 22 kDa, while endogenous is a mixture), and the biomarker test, which measures IGF-1 and P-III-NP (procollagen type III N-terminal peptide) levels that rise during GH administration. Neither approach is a simple peptide detection assay; both rely on indirect markers of GH excess rather than identification of the administered protein itself.
The Cat-and-Mouse Problem: Designer Peptides
The development of novel peptide sequences designed to evade detection represents the primary ongoing challenge. Judak et al. (2021) noted that the annually renewed WADA prohibited list now explicitly names an increasing number of peptides, reflecting the expanding landscape of misuse.[1]
Several evasion strategies are employed. Modified peptides with non-natural amino acid substitutions may not match the fragmentation patterns in existing detection databases. Peptides administered at low doses may fall below detection limits, particularly when testing relies on urine where peptide concentrations are lower than in blood. Novel sequences not yet catalogued by anti-doping databases would be invisible to targeted screening methods.
Anti-doping science counters with three approaches. First, non-targeted or "full scan" mass spectrometry acquires data on all detectable masses, allowing retrospective analysis when new prohibited substances are identified. A sample analyzed today can be re-examined years later for a substance that was not on the prohibited list at the time of collection. WADA-accredited laboratories store samples for up to 10 years, creating an extended window of accountability. Several high-profile doping cases have resulted from reanalysis of samples stored for years using newer, more sensitive methods.
Second, the Athlete Biological Passport (ABP) tracks longitudinal patterns in an athlete's own blood parameters. Changes in growth hormone isoforms, IGF-1 levels, or hematological markers can indicate peptide hormone use even when the specific substance is not directly detected. The ABP does not identify which peptide was used; it identifies that something altered the athlete's endocrine profile in a way inconsistent with natural variation. This indirect approach catches doping that direct detection methods miss.
Third, intelligence-led testing combines information from athlete whereabouts data, supply chain investigations, and digital intelligence (online purchases of peptide products) to target specific athletes for testing at times when detection is most likely. The increasing availability of peptides through online vendors creates a digital trail that anti-doping organizations can use to focus limited testing resources.
Lange et al. (2020) explicitly included glycine derivatives of GHRPs that were designed to circumvent testing in their 46-analyte dried blood spot method, demonstrating that anti-doping laboratories are proactively targeting anticipated evasion molecules.[4]
Limitations and Open Questions
Detection windows remain short for many peptides. Intact peptide hormones are cleared rapidly from blood and urine. GHRP-2's parent compound is undetectable in urine after oral dosing; only the metabolite persists for 20 hours. For an athlete who microdoses a peptide and trains the following day, the testing window may already be closed by the time an out-of-competition test occurs.
Urine testing has fundamental limitations for certain peptides. The failure to detect ghrelin in urine by mass spectrometry suggests that some endogenous-analogue peptides may not be reliably detected in this matrix. As blood-based testing (including DBS) expands, this limitation becomes less critical, but many testing programs still rely primarily on urine.
The gap between equine and human data. Several detection methods, including those for TB-500 and ibutamoren metabolites, were developed in horses rather than humans. While the general analytical approach transfers, metabolite profiles may differ between species, and human pharmacokinetic data for many banned peptides is sparse because ethical constraints prevent controlled administration studies.
Pre-analytical variables affect results. Delcourt et al. (2025) showed that improper sample handling (delayed plasma separation) can artificially elevate TB4 concentrations due to cell lysis.[7] Similar pre-analytical effects may apply to other endogenous peptides, potentially producing false positives or confounding the interpretation of borderline results.
Coverage is incomplete. The WADA prohibited list includes catch-all language banning "other growth factors or growth factor modulators" beyond those explicitly named. Enforcement against unnamed substances requires that laboratories either have specific methods or can identify them through non-targeted screening, which is not guaranteed. The proliferation of online peptide vendors selling "research chemicals" with minimal oversight means new sequences enter the market faster than analytical methods can be developed and validated. WADA's simplified testing procedure for new potentially performance-enhancing peptide hormones aims to accelerate method development, but the regulatory cycle still lags behind market availability.
Testing frequency and timing remain the weakest link. Even perfect analytical methods cannot detect peptide doping if the athlete is not tested during the detection window. The International Testing Standard requires anti-doping organizations to conduct tests based on risk assessment and intelligence, but most athletes in most sports are tested infrequently. An athlete who uses peptides during a training block and stops before competition has a reasonable chance of clearing detection thresholds, particularly for peptides with short detection windows like GHRPs.
The Bottom Line
Peptide doping detection has advanced dramatically over the past decade, driven by LC-HRMS technology that can screen for 40-50 banned peptides in a single run. BPC-157, TB-500, GHRPs, and ghrelin all have validated detection methods, though each presents unique analytical challenges. Metabolite-based detection extends windows for rapidly cleared peptides, stable isotope labeling has mapped BPC-157's degradation pathways, and synthesis impurity detection can distinguish synthetic from endogenous thymosin beta-4. Dried blood spots are enabling less invasive sample collection while maintaining analytical sensitivity. The primary remaining challenges are short detection windows, the urine matrix's limitations for some peptides, and the continuous emergence of designer peptide analogues engineered to evade current methods.